Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

SparkCures ID 99
Developed By Bristol-Myers Squibb
Generic Name Nivolumab
Additional Names BMS-936558
Treatment Classifications
Treatment Targets

Clinical Trials


There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Bristol-Myers Squibb to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners